Financial Ratios Henan Lingrui Pharmaceutical Co., Ltd.
Equities
600285
CNE000001501
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.51 CNY | +0.89% |
|
-0.37% | +3.86% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.97 | 6.49 | 5.98 | 8.07 | 9.24 | |||||
Return on Total Capital | 8.11 | 9.31 | 9.2 | 12.86 | 14.63 | |||||
Return On Equity % | 14.28 | 15.73 | 19.21 | 21.21 | 24.58 | |||||
Return on Common Equity | 14.39 | 15.75 | 19.27 | 21.27 | 24.65 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 76.67 | 73.72 | 72.1 | 73.17 | 75.77 | |||||
SG&A Margin | 57.56 | 55.07 | 53.56 | 50.58 | 50.34 | |||||
EBITDA Margin % | 16.82 | 16.62 | 15.44 | 20.07 | 22.72 | |||||
EBITA Margin % | 14.32 | 14.39 | 13.33 | 18.08 | 20.99 | |||||
EBIT Margin % | 13.88 | 13.98 | 12.96 | 17.78 | 20.67 | |||||
Income From Continuing Operations Margin % | 13.91 | 13.46 | 15.5 | 17.16 | 20.64 | |||||
Net Income Margin % | 13.96 | 13.42 | 15.5 | 17.16 | 20.64 | |||||
Net Avail. For Common Margin % | 13.96 | 13.42 | 15.5 | 17.16 | 20.64 | |||||
Normalized Net Income Margin | 10.24 | 9.61 | 9.78 | 12.13 | 13.97 | |||||
Levered Free Cash Flow Margin | 11.53 | 26.13 | 19.45 | 19.09 | 15.96 | |||||
Unlevered Free Cash Flow Margin | 11.56 | 26.17 | 19.47 | 19.09 | 15.97 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.69 | 0.74 | 0.74 | 0.73 | 0.72 | |||||
Fixed Assets Turnover | 3.12 | 3.68 | 4.17 | 4.89 | 5.47 | |||||
Receivables Turnover (Average Receivables) | 3.44 | 4.72 | 6.36 | 6.54 | 7.08 | |||||
Inventory Turnover (Average Inventory) | 1.76 | 1.86 | 1.83 | 1.86 | 1.88 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.8 | 1.48 | 1.47 | 1.37 | 1.31 | |||||
Quick Ratio | 1.45 | 1.16 | 1.16 | 1.11 | 1.07 | |||||
Operating Cash Flow to Current Liabilities | 0.42 | 0.59 | 0.49 | 0.43 | 0.47 | |||||
Days Sales Outstanding (Average Receivables) | 106.34 | 77.33 | 57.41 | 55.78 | 51.68 | |||||
Days Outstanding Inventory (Average Inventory) | 207.94 | 195.86 | 199.34 | 195.9 | 194.64 | |||||
Average Days Payable Outstanding | 45.53 | 35.55 | 29.76 | 26.32 | 31.96 | |||||
Cash Conversion Cycle (Average Days) | 268.75 | 237.63 | 226.98 | 225.36 | 214.36 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 7.15 | 12.33 | 6.2 | 7.43 | 3.21 | |||||
Total Debt / Total Capital | 6.67 | 10.98 | 5.84 | 6.92 | 3.11 | |||||
LT Debt/Equity | - | 0.35 | 0.24 | 0.25 | 0.21 | |||||
Long-Term Debt / Total Capital | - | 0.31 | 0.23 | 0.23 | 0.21 | |||||
Total Liabilities / Total Assets | 32.84 | 39.72 | 41.11 | 41.35 | 38.6 | |||||
EBIT / Interest Expense | 293.15 | 198.53 | 341.97 | 2.98K | 2.82K | |||||
EBITDA / Interest Expense | 355.17 | 236.92 | 408.99 | 3.37K | 3.11K | |||||
(EBITDA - Capex) / Interest Expense | 290.11 | 196.36 | 385.26 | 3.26K | 2.66K | |||||
Total Debt / EBITDA | 0.42 | 0.63 | 0.34 | 0.31 | 0.12 | |||||
Net Debt / EBITDA | -1.69 | -2.09 | -2.79 | -2.08 | -1.77 | |||||
Total Debt / (EBITDA - Capex) | 0.52 | 0.76 | 0.36 | 0.32 | 0.14 | |||||
Net Debt / (EBITDA - Capex) | -2.07 | -2.53 | -2.96 | -2.15 | -2.07 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.09 | 15.52 | 11.45 | 10.31 | 5.72 | |||||
Gross Profit, 1 Yr. Growth % | 7.45 | 11.3 | 9 | 11.95 | 9.47 | |||||
EBITDA, 1 Yr. Growth % | -1.06 | 16.37 | 3.52 | 43.45 | 19.67 | |||||
EBITA, 1 Yr. Growth % | -1.46 | 18.67 | 3.28 | 49.63 | 22.7 | |||||
EBIT, 1 Yr. Growth % | -1.55 | 19.05 | 3.35 | 51.37 | 22.89 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 10.66 | 11.75 | 28.37 | 22.1 | 27.19 | |||||
Net Income, 1 Yr. Growth % | 10.55 | 11.08 | 28.71 | 22.09 | 27.19 | |||||
Normalized Net Income, 1 Yr. Growth % | 14.72 | 8.52 | 13.4 | 35.98 | 21.68 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 11.91 | 11.34 | 28.37 | 22.47 | 27.72 | |||||
Accounts Receivable, 1 Yr. Growth % | 9.98 | -39.15 | 18.74 | -2.53 | -2.01 | |||||
Inventory, 1 Yr. Growth % | 15.6 | 29.26 | 13.54 | -3.92 | -6.93 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.7 | 0.4 | -3.57 | -8.34 | -2.56 | |||||
Total Assets, 1 Yr. Growth % | 4.28 | 9.7 | 14.53 | 9.84 | 5.13 | |||||
Tangible Book Value, 1 Yr. Growth % | 5.61 | -1.72 | 14.95 | 10.28 | 10.83 | |||||
Common Equity, 1 Yr. Growth % | 4.65 | -1.46 | 11.93 | 9.42 | 10.09 | |||||
Cash From Operations, 1 Yr. Growth % | 0.08 | 87.71 | -1.27 | -2.57 | 7.68 | |||||
Capital Expenditures, 1 Yr. Growth % | 21.65 | 7.08 | -64.9 | -21.47 | 443.02 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 13.27 | 166.26 | -13.54 | 15.73 | -9.58 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 10.66 | 166.02 | -13.59 | 15.6 | -9.57 | |||||
Dividend Per Share, 1 Yr. Growth % | 33.33 | 25 | 20 | 33.33 | 12.5 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.57 | 11.75 | 13.47 | 10.88 | 7.99 | |||||
Gross Profit, 2 Yr. CAGR % | 7.19 | 9.24 | 10.15 | 10.47 | 10.7 | |||||
EBITDA, 2 Yr. CAGR % | 4 | 6.28 | 9.76 | 21.86 | 31.02 | |||||
EBITA, 2 Yr. CAGR % | 4.75 | 6.93 | 10.71 | 24.31 | 35.5 | |||||
EBIT, 2 Yr. CAGR % | 4.9 | 7.02 | 10.93 | 25.08 | 36.39 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 14.89 | 11.2 | 19.77 | 25.19 | 24.62 | |||||
Net Income, 2 Yr. CAGR % | 15.67 | 10.81 | 19.57 | 25.35 | 24.61 | |||||
Normalized Net Income, 2 Yr. CAGR % | 16.25 | 11.57 | 10.93 | 24.56 | 28.63 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 17.93 | 11.63 | 19.55 | 25.38 | 25.06 | |||||
Accounts Receivable, 2 Yr. CAGR % | 12.41 | -18.19 | -15 | 7.58 | -2.27 | |||||
Inventory, 2 Yr. CAGR % | 1.17 | 22.24 | 21.15 | 4.45 | -5.44 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -3.26 | -2.19 | -1.61 | -5.99 | -5.5 | |||||
Total Assets, 2 Yr. CAGR % | 5.44 | 6.96 | 12.09 | 12.16 | 7.46 | |||||
Tangible Book Value, 2 Yr. CAGR % | 6.54 | 1.88 | 6.29 | 12.59 | 10.55 | |||||
Common Equity, 2 Yr. CAGR % | 5.39 | 1.55 | 5.02 | 10.67 | 9.75 | |||||
Cash From Operations, 2 Yr. CAGR % | 1.62 | 37.06 | 36.13 | -1.93 | 2.42 | |||||
Capital Expenditures, 2 Yr. CAGR % | 17.36 | 14.13 | -38.69 | -47.5 | 106.5 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 29.93 | 72.17 | 48.61 | -3.25 | 1.15 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 26.13 | 70.09 | 48.51 | -3.32 | 1.1 | |||||
Dividend Per Share, 2 Yr. CAGR % | 63.3 | 29.1 | 22.47 | 26.49 | 22.47 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.05 | 9.47 | 11.65 | 12.41 | 9.13 | |||||
Gross Profit, 3 Yr. CAGR % | 9.93 | 8.47 | 9.16 | 10.75 | 10.13 | |||||
EBITDA, 3 Yr. CAGR % | 9.65 | 7.29 | 5.36 | 20 | 21.13 | |||||
EBITA, 3 Yr. CAGR % | 9.09 | 8.38 | 5.7 | 22.4 | 23.77 | |||||
EBIT, 3 Yr. CAGR % | 9.39 | 8.58 | 5.78 | 23.04 | 24.34 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 12.98 | 13.83 | 16.65 | 20.54 | 25.85 | |||||
Net Income, 3 Yr. CAGR % | 14.45 | 14.12 | 16.48 | 20.4 | 25.96 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.9 | 13.61 | 12.18 | 18.97 | 23.59 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 16.01 | 15.69 | 16.95 | 20.52 | 26.16 | |||||
Accounts Receivable, 3 Yr. CAGR % | 7.44 | -8.39 | -7.38 | -11.03 | 4.28 | |||||
Inventory, 3 Yr. CAGR % | -3.17 | 9.78 | 19.27 | 12.14 | 0.51 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -3.3 | -2.06 | -2.65 | -3.9 | -4.86 | |||||
Total Assets, 3 Yr. CAGR % | 1.49 | 6.84 | 9.42 | 11.34 | 9.77 | |||||
Tangible Book Value, 3 Yr. CAGR % | 2.88 | 3.72 | 6.06 | 7.6 | 12 | |||||
Common Equity, 3 Yr. CAGR % | 2.08 | 3.06 | 4.9 | 6.47 | 10.47 | |||||
Cash From Operations, 3 Yr. CAGR % | 62 | 24.69 | 22.86 | 21.77 | 1.18 | |||||
Capital Expenditures, 3 Yr. CAGR % | -34.67 | 13.83 | -22.96 | -33.42 | 14.39 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 225.36 | 64.08 | 34.97 | 33.72 | -6.11 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 932.63 | 60.83 | 33.86 | 33.61 | -6.16 | |||||
Dividend Per Share, 3 Yr. CAGR % | 38.67 | 49.38 | 25.99 | 25.99 | 21.64 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 16.54 | 13.35 | 10.18 | 10.03 | 10.17 | |||||
Gross Profit, 5 Yr. CAGR % | 21.46 | 15.56 | 9.97 | 9.26 | 9.78 | |||||
EBITDA, 5 Yr. CAGR % | 17.76 | 15.77 | 9.27 | 12.9 | 14.96 | |||||
EBITA, 5 Yr. CAGR % | 18.71 | 16.76 | 9.25 | 14.49 | 16.74 | |||||
EBIT, 5 Yr. CAGR % | 18.92 | 16.92 | 9.49 | 14.9 | 17.1 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 19.51 | 0.84 | 15.65 | 18.25 | 19.77 | |||||
Net Income, 5 Yr. CAGR % | 19.8 | 0.9 | 16.47 | 18.49 | 19.67 | |||||
Normalized Net Income, 5 Yr. CAGR % | 19.81 | 0.14 | 14.47 | 17.87 | 18.64 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 18.43 | 1.13 | 17.42 | 19.48 | 20.13 | |||||
Accounts Receivable, 5 Yr. CAGR % | 30 | 5.37 | -2.17 | -2.31 | -5.37 | |||||
Inventory, 5 Yr. CAGR % | 2.14 | -2.41 | 5.91 | 7.61 | 8.7 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.46 | 1.81 | -2.62 | -3.65 | -3.8 | |||||
Total Assets, 5 Yr. CAGR % | 4.07 | 4.93 | 5.6 | 8.94 | 8.63 | |||||
Tangible Book Value, 5 Yr. CAGR % | 5.27 | 0.89 | 4.23 | 7.18 | 7.84 | |||||
Common Equity, 5 Yr. CAGR % | 6.03 | 1.78 | 3.25 | 6.04 | 6.81 | |||||
Cash From Operations, 5 Yr. CAGR % | 14.85 | 67.96 | 51.11 | 13.27 | 14.24 | |||||
Capital Expenditures, 5 Yr. CAGR % | -5.91 | -18.81 | -36.31 | -16.47 | 14.29 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 23.26 | 16.57 | 136.99 | 31.73 | 18.67 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 20.64 | 17.15 | 373.76 | 30.12 | 18.06 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 10.76 | 31.95 | 39.77 | 24.57 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















